Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylcholine + vasoactive intestinal polypeptide
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intradermal, Iontophoresis, Intracavernosal, Intra-arterial, Intracerebral
01
Overview
Acetylcholine + vasoactive intestinal polypeptide is a combination of two endogenous neurotransmitters and vasodilators. Acetylcholine (ACh) is a classical neurotransmitter involved in cholinergic signaling, while vasoactive intestinal polypeptide (VIP) is a neuropeptide with potent vasodilatory and smooth muscle relaxant properties. When administered together, these agents have been shown to produce synergistic effects on vascular tone and smooth muscle relaxation in various tissues, including the skin, salivary glands, corpus cavernosum (erectile tissue), and cerebral vessels. The combination has been studied experimentally for its ability to induce strong vasodilation and modulate sensory responses such as pain or pruritus. Mechanistically, ACh acts primarily via muscarinic receptors to induce endothelium-dependent vasodilation through nitric oxide release; VIP acts via VPAC1R/VPAC2R receptors to activate adenylyl cyclase and increase cAMP levels in target cells[1][2][5][6][7]. The combination may be used experimentally to probe neurovascular function or as a research tool in studies of autonomic regulation.
- Other names
- acetylcholine + VIPACh + VIP
02
Targets
CHRM3 (M3)ADCYAP1R1 (Pituitary adenylate cyclase-activating polypeptide receptor PAC1)VIPR1 (Vasoactive intestinal peptide receptor 1)VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on acetylcholine + vasoactive intestinal polypeptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylcholine + vasoactive intestinal polypeptide.